Clinical Study to Evaluate The Cardioprotective Effect of Pentoxifylline Against Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 25, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

December 31, 2026

Conditions

Doxorubicin Induced CardiotoxicityBreast Cancer

Interventions

DRUG

Pentoxifylline 400mg plus chemotherapy

patient will receive standard chemotherapy for breast cancer plus pentoxifylline 400 mg orally 3 times per day with meals.

Trial Locations (1)

RECRUITING

Damnhour Oncology Center, Damanhūr

All Listed Sponsors

lead

Tanta University

OTHER